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S UMMA R Y
The tuberculosis (TB) control strategy in the Republic of
Karakalpakstan, Uzbekistan, is being changed to decen-
tralised out-patient care for most TB patients by the
Government of Uzbekistan, in collaboration with the
international medical humanitarian organisation
Me´decins Sans Frontie`res. Ambulatory treatment of
both drug-susceptible and drug-resistant TB from the
first day of treatment has been recommended since
2011. Out-patient treatment of TB from the beginning
of treatment was previously prohibited. However, the
current Uzbek health financing system, which evolved
from the Soviet Semashko model, offers incentives that
work against the adoption of ambulatory TB treatment.
Based on the ‘Comprehensive TB Care for All’
programme implemented in Karakalpakstan, we de-
scribe how existing policies for the allocation of health
funds complicate the scale-up of ambulatory-based
management of TB.
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OF THE 15 COUNTRIES of the former Soviet
Union, 13 are among the world’s 27 high multi-
drug-resistant TB (MDR-TB) burden countries. Some
of the world’s highest MDR-TB rates are found
among new (13–26%) and retreatment TB cases (55–
58%) in the Central Asian countries of Kazakhstan,
Kyrgyzstan, Tajikistan and Uzbekistan.1 Overall,
there are concerns that the cost of MDR-TB control
may become unaffordable unless the growing burden
of MDR-TB is reversed in the near future with new
drugs and diagnostics, as well as scale-up of cost-
effective models of care.2
One of Uzbekistan’s highest TB burden areas is the
region of Karakalpakstan, home to 1.7 million
people. According to its Ministry of Health (MoH),
Karakalpakstan’s TB prevalence and mortality were
more than twice the national average in 2013 (107.7
vs. 50.8 per 100 000 population and 10 vs. 3.9/
100 000, respectively). Its MDR-TB rates are nearly
twice the Uzbek average (40.8% vs. 23.2% among
new and 78.1% vs. 62.0% among retreatment TB
cases in 2010).3 The severity of this situation is
perceived to be associated with the desiccation of the
Aral Sea and its socio-economic consequences.
In response to the TB burden in Karakalpakstan,
the MoH of Uzbekistan, with the support of
Me´decins Sans Frontie`res (MSF), launched the DOTS
strategy in 1998. Although the programme was
initiated successfully, performance indicators gradu-
ally deteriorated. To elucidate the reasons for the
declining efficacy of the DOTS strategy, drug
susceptibility testing (DST) of TB patients was
introduced, starting in four districts of Karakalpak-
stan. The DST results indicated high rates of MDR-
TB.4,5 As a result of this, a DOTS-Plus pilot project to
identify and treat MDR-TB patients with individual-
ised care was initiated in 2003 for the first time in
Uzbekistan.6 In 2011, the ‘Comprehensive TB Care
for All’ programme in Karakalpakstan introduced
treatment for drug-susceptible and MDR-TB patients
on an ambulatory basis throughout treatment,
eliminating the previous compulsory phase of hospi-
talisation for TB patients.7
Ambulatory treatment is common practice for
drug-susceptible TB, whereas MDR-TB patients
may receive treatment as either out-patients or in-
patients in secondary or tertiary facilities.1 TheWorld
Health Organization (WHO) and MSF recommend
that, where possible, patients with MDR-TB, like
those with drug-susceptible TB, should be treated as
out-patients using ambulatory care rather than
hospital-based treatment.7,8 Ambulatory TB care is
expected to reduce the risk of nosocomial cross-
infection with different or more resistant strains of
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Mycobacterium tuberculosis during in-patient treat-
ment, and offers patients greater independence during
treatment.9 Early evidence indicates that ambulatory
MDR-TB treatment appears to be cost-effective and
no less effective than hospital-based models.10,11
However, remodelling an existing in-patient-based
TB care system towards a primarily ambulatory
model of care can require policy and legislative
changes, including changes in health financing
mechanisms, to facilitate the adoption of the new
treatment model.
The present Uzbek financing mechanisms of the
post-Semashko health care system allocate resources
to TB hospitals based on the number of beds provided.
The number of beds to be provided is typically
extrapolated from past use, and is adjusted according
to the facility’s bed occupancy rate. This mechanism
lacks incentives for referrals to ambulatory care.
Ambulatory care is funded based on the population
size, age and sex structure of the area served. Regular
financing of out-patient care is thus unresponsive to
rapidly changing patient numbers. Both financing
mechanisms complicate the scale-up of a model of
comprehensive ambulatory TB care for drug-suscepti-
ble and MDR-TB patients in the Republic of
Karakalpakstan, in Uzbekistan.7
In the present paper, we present key aspects of the
TB services in Karakalpakstan and the traditional
financing mechanisms in place for the public health
services in Uzbekistan, which characterise the funding
of the TB services in Karakalpakstan. We then discuss
how the existing financing mechanisms affect the
transition from hospital-based TB management to a
comprehensive ambulatory TB care programme.
TB SERVICES IN KARAKALPAKSTAN
TB services in Karakalpakstan are organised as part
of Uzbekistan’s public health care sector. Uzbekistan’s
health system has evolved from the Soviet Semashko
health care model. The public sector constitutes the
core of the centralised hierarchical health system, in
which the most prevalent mode of regulation is policy
formulation. Policies are set by higher administrative
levels within the health system, and subordinate levels
are expected to follow them. Traditionally, neither
fiscal nor other forms of incentive form part of the
system used for regulating health care providers.12
The TB services operate in-patient and out-patient
health facilities, which are funded by independent
budgets from the Ministry of Finance (MoF).
TB care in some administrative districts, called
rayons, is provided in collaboration with MSF. The
treatment plan for each TB patient is prescribed by
TB specialists. All anti-tuberculosis treatment is
provided free of charge. Anti-tuberculosis drugs
prescribed by the TB services are primarily provided
by the Global Fund to Fight AIDS, Tuberculosis and
Malaria (Geneva, Switzerland). MSF supports the TB
services with staff, training and diagnostic tools. TB
patients were not allowed to receive treatment
elsewhere apart from at the public TB services of
the regional MoH. In practice, in addition to
institutionalised TB care, self-treatment, non-stan-
dard treatment provided by doctors and traditional
healing are also common.
There are various entry points to diagnosis and
treatment. Patients with TB symptoms usually
contact the TB services through the pathways
described in Table 1. Many patients seek a consulta-
tion directly with a designated TB doctor, who is the
only medical doctor with the authority to give an
official diagnosis of TB. TB doctors are responsible
for all TB activities within their rayon. Each rayon
has one head TB doctor, one deputy head TB doctor
and other TB doctors. Typically, there are two out-
patient TB doctors in rayons with a population of up
to 50 000, and at least four out-patient TB doctors,
one of whom is a TB paediatrician, in rayons with a
population of 100 000 or more. Rayons with in-
patient TB facilities also have in-patient TB doctors.
In-patient care
Each TB hospital is headed by a TB doctor who
assumes medical responsibilities and acts as the
hospital’s administrative and financial director. Hos-
pital budgets are closely linked to the number of beds
occupied. The number of hospital beds determines
the number of staff assigned to the hospital, which
only treats in-patients. Other resource needs are
determined by the MoH in the same way. The MoF
can request the MoH to reduce the planned bed
capacity if bed occupancy rate falls below 80% of the
targeted bed occupancy of 310 days per year for a
prolonged period of time. To date, theMoH has made
proactive downward adjustments of TB bed capacity.
In 2013, the estimated operating costs of TB
hospitals in Nukus City were as follows: 30% of total
expenditure for employees, 10% on food, 55% on
drugs, medical devices and diagnostic tools (net of
donated drugs and diagnostic tools), and 5% on
utilities and other expenses for the maintenance of
the TB facilities (e.g., utilities, repair and overhaul,
purchase of inventory). In 2013, the average actual cost
for maintaining one hospital bed for drug-susceptible
TB patients in Nukus City was Uzbekistani som
($UZS) 30169 per day and $UZS 1206756 per case
treated ($UZS 3000 ’ E1). Maintaining one bed for
an MDR-TB patient cost $UZS 42477/day and $UZS
4247713/case treated. The average length of hospi-
talisation was 40 days for patients with drug-suscep-
tible TB and 100 days for patients with MDR-TB.
Out-patient care
Out-patient TB care is administered through DOTS
corners, operated by out-patient clinics. Clinic staff,
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which includes ambulatory TB doctors, provide only
out-patient treatment and commute between off-site
locations. The administration of ambulatory DOTS
treatment for TB patients in DOTS corners is
typically assigned to one of the clinic nurses, who
also performs other tasks in the clinic. The duties of
the DOTS corner staff include home visits to TB
patients if they do not show up at a DOTS corner for
the administration of drugs.
In rayons covered by the Comprehensive TB Care
for All programme, 38% of TB patients were given
ambulatory treatment in DOTS corners from the
diagnosis of active TB up toMarch 2014. Of the total
number of patients who received treatment at the
DOTS corners, 58% had MDR-TB. Treatment for
drug-susceptible patients usually lasted between 6
and 8 months if ambulatory from the start, and
between 4 and 5 months if initiated in a TB hospital.
The usual duration of ambulatory treatment for
patients with MDR-TB was 2 years.
The budget and resources allocated to an out-
patient clinic are based on the size of the population
of the catchment area. These are adjusted for the age
and sex composition of the population in the
catchment area, but are not directly related to the
number of TB out-patients. Most of the ambulatory
care budget funded by the MoF is spent on salaries
and related expenses. The costs of transportation
incurred by the TB services are not included in the
out-patient clinic budget. Instead, each rayon is
provided with a vehicle to accommodate the various
transportation needs, such as visits to patients who do
not attend the DOTS corner, visits to very sick
patients who receive treatment at home, or commut-
ing between TB facilities.
TRANSITION FROM IN-PATIENT TO OUT-
PATIENT TUBERCULOSIS CARE
Although post-Semashko health care systems have a
tradition of providing hospital-based care, the Kar-
akalpakstan MoH introduced policy and legislative
changes to allow ambulatory DOTS for most TB
patients. Before the MoH started the Comprehensive
TB Care for All programme in collaboration with
MSF, it was mandatory in Karakalpakstan for all TB
patients, irrespective of drug susceptibility, to start
treatment in hospital (decree no. 16013). Patients
diagnosed with active MDR-TB were admitted for an
intensive treatment phase of at least 8 months, or
longer if additional treatment was needed to achieve
sputum conversion. Since the Karakalpakstan’s MoH
February 2011 ‘pricaz’ (decree) no. 39, ambulatory
TB treatment from day 1 has been the recommended
strategy for both drug-susceptible TB and MDR-TB,
unless the patient’s condition requires special medical
attention that cannot be provided at home or in an
ambulatory setting.14 Thus, a diagnosis of TB per se
ceased to require or justify hospital admission. TB
patients in areas covered by the Comprehensive TB
Care for All programme (nine rayons and two cities
by May 2014) can therefore now receive treatment
for drug-susceptible TB and MDR-TB on an ambu-
latory basis in DOTS corners without the mandatory
in-hospital phase.
As of March 2014, the programme had enrolled
1832 of 4838 newly diagnosed TB patients in the
rayons where Comprehensive TB Care for All has
been implemented; these patients received all treat-
ment as out-patients. Of these, 1055 were diagnosed
with MDR-TB, and 777 with drug-susceptible TB.
During the same period, about 15 000 patients were
admitted to TB hospitals in Karakalpakstan for the
treatment of active TB, relapse preventive treatment
and palliative treatment, or to confirm disability
status due to ‘chronic TB’ . Putting these 1832 TB
patients on ambulatory treatment resulted in an
estimated savings of 136 580 bed-days in TB hospi-
tals, or 374 TB hospital beds/year, i.e., an average
duration of hospitalisation of 40 days for each drug-
susceptible TB patient, and 100 days for each MDR-
TB patient given ambulatory treatment throughout.
Before the Comprehensive TB Care for All pro-
gramme, there were 1425 hospital beds in specialised
TB care facilities in the Republic of Karakalpakstan.
With the start of the programme, this was reduced by
165 TB beds, and some of the remaining facilities
were reconstructed based on decree no. 62 of the
Table 1 Patient pathways to TB care
First contact point First contact person Potential diagnostic tests Referral to Treatment decision
Out-patient department, polyclinic, SVP*
TB doctor Sputum sample,
fluoroscopy, X-ray
None In- or out-patient; if out-
patient, at health facility
or home-based
General practitioner,
internist or pulmonologist
Sputum sample,
fluoroscopy, X-ray
TB doctor None
Branch of SVP (previously FAP)*
Nurse Sputum sample General practitioner
or TB doctor
None
*Rural health posts.
TB¼ tuberculosis; SVP¼ selskie vrachebniye punkt (primary health care facilities); FAP¼ Feldsher-Accoucheur point (local health post).
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Government of the Republic of Uzbekistan.15 A
further reduction of hospital capacity for TB patients
seems feasible, and is planned by the MoH, as the TB
bed occupancy rate in Karakalpakstan was 63% of
the 310 days/year targeted in 2012, and dropped to
41% in 2013.
The introduction of the Comprehensive TB Care
for All programme helped reduce TB hospital
capacity, but at the same time it significantly
increased the workload of the staff in the out-patient
clinics. Despite the transition to ambulatory TB care
and the resultant savings in the in-patient sector, no
additional resources, except for a one-off 50% salary
increase for the staff of all TB facilities (decree no.
62), could be allocated to the ambulatory TB services
by the MoH due to the population-based funding of
ambulatory care by theMoF.15 After reducing the bed
capacity of TB hospitals by 12%, there is still
overcapacity, and strategic bed occupancy occurs,
e.g., by putting pressure on subordinates to keep beds
filled, calling external doctors to refer patients, or not
transferring patients to ambulatory care at the earliest
possible stage.
CHALLENGES TO OVERCOME
The MoH and MSF, whose aim is to scale up
ambulatory TB care, face challenges similar to those
confronting the health systems of the former Soviet
Union states after independence. Treatment and
financing mechanisms are hospital-oriented, despite
the fact that several procedures can be carried out
more cost-effectively in ambulatory settings, and the
ambulatory sector needed for comprehensive out-
patient care is underdeveloped and/or under-
financed.16,17
Budgeting process
The inflexible financing mechanisms for anti-tuber-
culosis treatment allocate separate budgets to in-
patient and out-patient care. Therefore, savings in the
hospital sector, for example, that were achieved
through the reduction of the TB bed capacity in
Karakalpakstan, cannot be reused directly by the
MoH within the TB services to financially strengthen
the ambulatory sector. Budget reallocation from in-
patient to out-patient TB services requires approval
by the MoF, which can, and so far to a large extent
does, decide to invest in areas other than ambulatory
management of TB.
In-patient care
The current Uzbek health system does not set
financial incentives to use fewer TB hospital beds.
On the contrary, hospitals face the risk of being
allocated fewer resources for TB care in the future if
less than 80% of the bed capacity planned for TB in-
patients is used. Furthermore, non-financial incen-
tives bias decision-making toward maintaining hos-
pital-based treatment. Failure to use allocated
resources might be perceived as a malfunction of
the current system, which focuses on monitoring the
quantity rather than the quality of the services it
delivers. Hospital staff enjoy a higher status, while
ambulatory staff in DOTS corners face a higher
workload. In-patient TB care is provided in urban
settings, unlike ambulatory care, which is mostly
carried out in rural areas, where working conditions
are more difficult.
Out-patient care
The budgeting process for ambulatory TB care is
based on an extrapolation of past financial expenses,
adjusted for changes in the population size and the
demographic characteristics of the catchment area of
an ambulatory facility. As a result, the financing
mechanism for ambulatory treatment has not pro-
vided more resources in the scale-up of ambulatory
anti-tuberculosis treatment. Given that the out-
patient budget is unrelated to changing patient
numbers, the increasing number of TB patients
admitted to ambulatory treatment has reduced the
resources available per patient and increased the
workload per member of staff in the ambulatory
facilities. Some ambulatory TB staff even pay for
professional phone calls or transportation out of their
own pocket when resources provided are insufficient
to cope with the workload.
DISCUSSION: TOWARD FINANCING
MECHANISMS THAT STRENGTHEN
AMBULATORY TB CARE
The MoH of Karakalpakstan and MSF have experi-
enced the need to look beyond addressing existing
input gaps,18 and they are attempting to find health
financing mechanisms that support the scale-up of
ambulatory anti-tuberculosis treatment. In principle,
it seems possible to achieve both a reduction in the
number of TB hospital beds and a strengthening of
ambulatory TB care within the health financing
mechanisms inherited from the Semashko model.
The past regulatory decisions of the Karakalpakstan
MoH to allow ambulatory treatment of patients with
drug-susceptible and MDR-TB from the day of
diagnosis, and to cut hospital capacity for TB
patients, are examples. However, the savings
achieved by reducing the number of the beds in in-
patient TB care cannot be directly reinvested in
ambulatory anti-tuberculosis treatment by the MoH
without permission from the MoF, or without
changing the financing system for the TB services.
A pragmatic approach to resolve these challenges
for TB care in Karakalpakstan might combine the
following: first, regulation for rough adjustments
through decrees that can take effect without delay.
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Second, changes to TB care financing mechanisms
that implement incentives to support transferring TB
patients to ambulatory care and sustainably finance
the growing number of out-patients on treatment.
Third, consideration of local capacity and contextual
factors to scale up TB care quickly, for example by
building on capacity already created within past
health reforms, such as the development of primary
health care, a previously newly developed ambulatory
health sector or case-based hospital financing, as is
being piloted in other areas of the Uzbek health sector
(Table 2).
CONCLUSION
Medical treatment of TB is part of an inherited
hospital-based system in Uzbekistan that evolved at a
time when alternative anti-tuberculosis treatment
options were not considered viable. Health facilities
providing ambulatory anti-tuberculosis treatment are
currently funded based on the size of the population
and the demographic characteristics in their catch-
ment area. As a result, health facilities are not
receiving additional financial resources to treat the
growing number of out-patients following the expan-
sion of ambulatory TB care. At the same time, TB
hospital financing is primarily based on in-patient
bed numbers and bed occupancy rates. These typical
post-Semashko health financing mechanisms provide
hospitals with a financial incentive for keeping
patients in hospital rather than discharging them at
the first opportunity, and do not incentivise the scale-
up of ambulatory anti-tuberculosis treatment. The
current financing mechanisms of the TB services in
Uzbekistan’s Karakalpakstan region therefore hinder
the scale-up of ambulatory-based management of
drug-susceptible TB and MDR-TB recommended by
the WHO and MSF. The likely consequences are
higher costs for the health system, an increased risk of
hospital-acquired TB cross-infection through avoid-
able hospitalisation, and possibly increased treatment
default rates in understaffed ambulatory TB servic-
es.9,10,19 As efforts to innovate systems and disease
response can be mutually reinforcing for the im-
provement of health outcomes, more discussion
about health financing mechanisms that support a
sustainable adoption of ambulatory treatment ap-
proaches for TB in post-Semashko health care
systems is needed to guide public health policy.20
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R E S UM E
La lutte contre la tuberculose (TB) dans la Re´publique
du Karakalpakstan, en Ouzbe´kistan, e´volue vers une
prise en charge de´centralise´e des soins en externe pour la
majorite´ des patients par le Gouvernement
d’Ouzbe´kistan en collaboration avec l’organisation
humanitaire me´dicale internationale Me´decins Sans
Frontie`res. Depuis 2011, le traitement ambulatoire de
la TB pharmacosensible ou re´sistante est recommande´
de`s le premier jour de traitement. Le traitement en
externe de la TB de`s sa mise en route e´tait jusque-la`
interdit. Le syste`me ouzbek actuel de financement de la
sante´, qui a e´volue´ a` partir du mode`le sovie´tique
Semashko, comporte cependant des incitations
contraires a` l’adoption du traitement ambulatoire. A
partir du programme de « Prise en charge comple`te des
soins de la TB pour tous » mis en œuvre au
Karakalpakstan, nous de´crivons les politiques
existantes en matie`re d’attribution des fonds de sante´
qui, a` notre avis, compliquent l’expansion d’une
strate´gie de traitement ambulatoire complet de la TB.
R E S UM E N
En la Repu´blica de Karakalpaksta´n, en Uzbekista´n, el
control de la tuberculosis (TB) ha evolucionado hacia un
enfoque descentralizado de atencio´n ambulatoria de la
mayorı´a de los pacientes tuberculosos por iniciativa del
gobierno de Uzbekista´n en colaboracio´n con la
organizacio´n internacional humanitaria Me´dicos sin
Fronteras. A partir del 2011 se recomienda el
tratamiento ambulatorio de los casos de TB
farmacosensible o farmacorresistente, desde el primer
dı´a del tratamiento. En el pasado, estaba prohibido
iniciar el tratamiento de la TB de manera ambulatoria.
Sin embargo, el actual sistema usbeko de financiamiento
de la salud, derivado del modelo sovie´tico Semashko,
ofrece incentivos que se oponen a la adopcio´n de un
tratamiento antituberculoso ambulatorio. En el presente
artı´culo, con base en el programa ‘Atencio´n integrada de
la tuberculosis para todos’ que se aplica en
Karakalpaksta´n, se describen las polı´ticas vigentes de
atribucio´n de fondos de salud que aparecen como frenos
a la ampliacio´n de escala de una estrategia de
tratamiento antituberculoso integral ambulatorio.
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